H. Curé

Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial.

M. Campone, G. Romieu, F. Bidard, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment results, survival and prognostic factors in 109 inflammatory breast cancers: univariate and multivariate analysis.

M. D. De Latour, F. Kwiatkowski, P. Chollet, 1993, European journal of cancer.

LANDSCAPE: An FNCLCC phase II study with lapatinib (L) and capecitabine (C) in patients with brain metastases (BM) from HER2-positive (+) metastatic breast cancer (MBC) before whole-brain radiotherapy (WBR).

M. Campone, G. Romieu, J. Pierga, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial)

T. Delozier, V. Bardou, P. Viens, 1999, British Journal of Cancer.

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

C. Tournigand, M. Espié, B. Weber, 2019, The Lancet.

Phase III randomized trial of high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients (pts) with advanced ovarian cancer (AOC): 5-year follow-up of a GINECO/FNCLCC/SFGM-TC study.

E. Pujade-Lauraine, M. Fabbro, H. Curé, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose chemotherapy for ovarian carcinoma: long-term results from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT).

P. Viens, F. Chauvin, J. Lotz, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long-term results.

M. Canis, J. Bay, P. Chollet, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate

F. Penault-Llorca, F. Kwiatkowski, P. Chollet, 2003, British Journal of Cancer.